<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916522</url>
  </required_header>
  <id_info>
    <org_study_id>COHERENT</org_study_id>
    <secondary_id>2020-004492-40</secondary_id>
    <nct_id>NCT04916522</nct_id>
  </id_info>
  <brief_title>The COlchicine HypERtENsion Trial</brief_title>
  <acronym>COHERENT</acronym>
  <official_title>COHERENT - The COlchicine HypERtENsion Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study to investigate the effects of colchicine on measures of vascular&#xD;
      and cardiac function in patients with hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an investigator-initiated, prospective, double-blind, placebo-controlled,&#xD;
      randomized clinical trial investigating the effects of colchicine in patients with&#xD;
      hypertension. The study population will consist of approximately 150 patients aged 18 years&#xD;
      and above with a diagnosis of hypertension and in active treatment with at least 1&#xD;
      antihypertensive drug. Patients will be randomized to either low-dose colchicine treatment&#xD;
      (0,5 mg once daily) or placebo. Treatment will continue for 6 months. Patients will be&#xD;
      assessed by measurement of pulse wave velocity (PWV), office blood pressure,&#xD;
      echocardiography, cardiac MRI, and blood samples at baseline and after 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Between-group difference in change in carotid-femoral pulse wave velocity at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change in office-measured systolic blood pressure at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change in office-measured diastolic blood pressure at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change in left ventricular mass assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change in left ventricular mass assessed by cardiac magnetic resonance imaging at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change in high sensitivity C-reactive protein at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in change in high sensitivity Troponin I at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Between-group difference in change in office-measured pulse pressure at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in central blood pressure assessed by pulse wave analysis at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in augmentation index assessed by pulse wave analysis at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left ventricular septal wall thickness assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left ventricular posterior wall thickness assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left ventricular ejection fraction assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in E/A ratio assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in e' assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in E/e' assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in E/e'sr assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left atrial volume assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in global longitudinal strain assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in myocardial work assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in aortic distensibility assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in aortic strain assessed by echocardiography at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left ventricular septal wall thickness assessed by cardiac magnetic resonance imaging at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left ventricular posterior wall thickness assessed by cardiac magnetic resonance imaging at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left ventricular ejection fraction assessed by cardiac magnetic resonance imaging at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in left atrial volume assessed by cardiac magnetic resonance imaging at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in myocardial fibrosis assessed by cardiac magnetic resonance imaging at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in myocardial inflammation assessed by cardiac magnetic resonance imaging at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in tumor necrosis factor alpha at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in pro B-type natriuretic peptide at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in interleukin-1 beta at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in interleukin-6 at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in interleukin-10 at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Between-group difference in change in interleukin-17 at 6 months</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>0.5 mg once daily</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Living address in the Capital Region of Denmark&#xD;
&#xD;
          2. Age &gt;18 years&#xD;
&#xD;
          3. Diagnosed with hypertension&#xD;
&#xD;
          4. Treatment with 1 or more antihypertensive medications&#xD;
&#xD;
          5. Must fulfill at least one of the following high-risk criteria:&#xD;
&#xD;
               1. Diagnosed with type 2 diabetes mellitus OR&#xD;
&#xD;
               2. Treatment with lipid-lowering medication for dyslipidemia OR&#xD;
&#xD;
               3. Treatment with 2 or more antihypertensive medications&#xD;
&#xD;
          6. Female patients should either not be of childbearing potential, defined as&#xD;
             postmenopausal for at least 1 year or surgically sterile, or is of childbearing&#xD;
             potential and practicing one of the following methods of contraception throughout the&#xD;
             study and for 30 days after study completion: Hormonal contraception (oral&#xD;
             contraceptives, contraceptive implant, injectable birth control, contraceptive patch,&#xD;
             or vaginal ring) or intrauterine device&#xD;
&#xD;
          7. Patients will have given written, informed consent and are able and willing to comply&#xD;
             with the requirements of the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Colchicine treatment for another cause, e.g. gout&#xD;
&#xD;
          2. Allergy/hypersensitivity to colchicine&#xD;
&#xD;
          3. Known or suspected secondary hypertension, e.g. renal artery stenosis&#xD;
&#xD;
          4. Uncontrolled hypertension (systolic BP &gt;180 mmHg or diastolic BP &gt;110 mmHg)&#xD;
&#xD;
          5. Known other cardiovascular disease (judged by the investigator), e.g. ischemic heart&#xD;
             disease, heart failure, significant valvular disease, arrhythmia, stroke, or&#xD;
             peripheral artery disease&#xD;
&#xD;
          6. History of malignancy of any organ system excluding a successfully treated&#xD;
             non-metastatic cutaneous squamous cell or basal cell carcinoma, localized prostate&#xD;
             cancer and/or localized carcinoma in situ of the cervix&#xD;
&#xD;
          7. Cirrhosis, chronic active hepatitis or other severe hepatic disease&#xD;
&#xD;
          8. Hemodialysis&#xD;
&#xD;
          9. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2&#xD;
&#xD;
         10. Systemic treatment with moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors or&#xD;
             P-glycoprotein inhibitors&#xD;
&#xD;
         11. Anemia, thrombocytopenia or leucopenia defined as any of the following measurements&#xD;
             within the last 3 months:&#xD;
&#xD;
               1. Hemoglobin &lt; 7 mmol/L&#xD;
&#xD;
               2. Platelet count &lt; 110 x 10^9/L&#xD;
&#xD;
               3. White blood cell count &lt; 3.0 x 10^9/L&#xD;
&#xD;
         12. Female patients who are pregnant, lactating, or considering becoming pregnant during&#xD;
             the study or for 6 months after study completion&#xD;
&#xD;
         13. Significant drug or alcohol abuse during the last year&#xD;
&#xD;
         14. Current use of or plans to initiate chronic systemic steroid therapy during the study&#xD;
             (topical or inhaled steroids are allowed)&#xD;
&#xD;
         15. Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic&#xD;
             diarrhea&#xD;
&#xD;
         16. Use of other investigational drugs within 30 days of the time of enrollment&#xD;
&#xD;
         17. Any surgical or medical condition, which in the opinion of the investigator, may place&#xD;
             the patient at higher risk from his/her participation in the study, or is likely to&#xD;
             prevent the patient from complying with the requirements of the study or completing&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niklas Dyrby Johansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev and Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niklas Dyrby Johansen, MD</last_name>
    <phone>+4520204794</phone>
    <email>niklas.dyrby.johansen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tor Biering-Sørensen, MD, PhD, MPH</last_name>
    <phone>+4528933590</phone>
    <email>tor.biering-soerensen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Dyrby Johansen, MD</last_name>
      <phone>+4520204794</phone>
      <email>niklas.dyrby.johansen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Tor Biering-Sørensen, MD, PhD, MPH</last_name>
      <phone>+4528933590</phone>
      <email>tor.biering-soerensen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Niklas Dyrby Johansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Niklas Dyrby Johansen</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Vascular Stiffness</keyword>
  <keyword>Pulse Wave Analysis</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Computed Tomography Angiography</keyword>
  <keyword>Hypertrophy, Left Ventricular</keyword>
  <keyword>Ventricular Function, Left</keyword>
  <keyword>Endomyocardial Fibrosis</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Coronary Atherosclerosis</keyword>
  <keyword>Colchicine</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

